Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

BACKGROUND: Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B (CHB) patients have an active liver disease with a high risk of progression to decompensated cirrhosis and hepatocellular carcinoma. The management strategy for HBeAg-negative CHB patients treated with nucleos(t)ide analogues (NU...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Dengming, Guo, Shimin, Chen, Wen, Chen, Xianli, Yan, Guohua, Wang, Jie, Li, Maoshi, Zhu, Peng, Huang, Hongfei, Wang, Yuming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850530/
https://www.ncbi.nlm.nih.gov/pubmed/24090287
http://dx.doi.org/10.1186/1471-2334-13-458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850530/
https://www.ncbi.nlm.nih.gov/pubmed/24090287
http://dx.doi.org/10.1186/1471-2334-13-458

Ejemplares similares